Nomenclature: A History Told Through Names
The history of ME/CFS is recorded in its changing names, each reflecting the dominant medical framework of its era:
| Period | Name | Framing |
|---|---|---|
| 1934 | atypical poliomyelitis | neurological — modeled on known virus |
| 1948 | Iceland disease / Akureyri disease | geographical — local phenomenon |
| 1955 | myalgic encephalomyelitis | neurological — introduced in Royal Free BMJ report |
| 1959 | benign myalgic encephalomyelitis | neurological — synthesized by Acheson |
| 1970 | mass hysteria (McEvedy) | psychiatric — outbreak reinterpreted |
| 1988 | chronic fatigue syndrome | somatization — “fatigue” replaces neurological framing |
| 1994 | chronic fatigue syndrome (Fukuda) | mixed — biological research allowed, trivializing name retained |
| 2003 | ME/CFS (Canadian Consensus) | neurological — “ME” restored, PEM required |
| 2015 | SEID / ME/CFS (IOM) | biological — explicit repudiation of psychosomatic model |
| 2022 | 8E49 postviral fatigue syndrome (ICD-11) | neurological — WHO classification maintained |
The 90-year arc of ME/CFS history from the 1934 Los Angeles outbreak to the 2025 DecodeME GWAS represents one of the most dramatic reversals in modern medical epistemology: a disease consistently documented with neurological features across 14 epidemics was reclassified as psychosomatic on the basis of negative standard laboratory tests, and then — through patient advocacy, systematic review, and molecular evidence — reestablished as a biological, genetically grounded neurological disorder.
The IOM 2015 report provided the institutional authority ((Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 2015)). The PACE trial controversy demonstrated that the psychosomatic treatment model was not merely unsupported but harmful ((Wilshire et al. 2018); (Geraghty, Hann, and Kurtev 2019)). The NIH 2024 study provided multi-system molecular validation ((Walitt et al. 2024)). The DecodeME GWAS demonstrated a polygenic architecture with brain tissue enrichment ((DecodeME Consortium, Ponting, et al. 2025)).
This history has practical consequences. Patients continue to encounter clinicians trained during the psychosomatic era who recommend graded exercise or dismiss symptoms as deconditioning. Diagnostic delays average 5–10 years. Research funding remains below 0.03% of the NIH budget. The clinical and institutional infrastructure needed to translate molecular findings into treatments does not yet exist. The history of ME/CFS is not complete — it is in active transition from its psychosomatic past to its biological future.
Consequence: The psychosomatic-to-biological transition documented in this history is not yet complete at the level of clinical practice, medical education, or research infrastructure — every molecular finding must still cross the translational gap between laboratory evidence and bedside care. Known certainty: 0.80 (IOM and NICE institutional authority; molecular evidence from NIH + DecodeME).
The outbreak pattern (1934–1985) is well-documented but poorly understood: why did 14 epidemics with virtually identical clinical features fail to accumulate into a recognized disease entity until Acheson’s 1959 synthesis? Each outbreak was investigated locally, classified under a provisional label (atypical polio, Iceland disease, Royal Free disease, epidemic neuromyasthenia), and forgotten — a pattern of institutional amnesia that delayed recognition by decades. This raises an epistemological question: how many rare or emerging diseases are currently scattered across the literature under different names, waiting for synthesis?
Consequence: The historical failure to aggregate outbreak reports into a unified disease entity is a reproducible error pattern that modern systematic review infrastructure should prevent — but only if institutions prioritize synthesis over novelty. Known certainty: 0.55 (historical pattern well-documented; generalization to other diseases is inductive).
The 1988 CDC decision to name the disorder “chronic fatigue syndrome” replaced a specific neurological descriptor (“myalgic encephalomyelitis”) with a generic symptom common to hundreds of conditions. Research on illness perception suggests that disease names influence clinical reasoning, patient credibility, and funding allocation. The question remains open: did the name “CFS” cause harm by semantically demoting a neurological disease to a fatigue complaint? Or was it a consequence of the psychosomatic framing already established by McEvedy? The causal direction matters: if names can shape medicine, nomenclature reform is a treatment intervention in its own right.
Consequence: If disease naming affects clinical outcomes through its impact on physician perception and patient credibility, then SEID or ME should replace CFS in all official contexts — a change that has not yet been completed despite IOM and NICE endorsement. Known certainty: 0.50 (correlational evidence; causal direction unproven by experiment — the counterfactual cannot be tested).
The 90-year history of ME/CFS condenses to a single structural pattern with profound implications for how medicine handles unexplained illness: (1) an outbreak or clinical pattern emerges with consistent phenomenology but negative standard laboratory tests; (2) the default medical response defaults to psychosomatic attribution, licensing treatment approaches that reinterpret biological symptoms as maladaptive beliefs and behaviors; (3) patient advocacy, methodological scrutiny, and advancing technology gradually accumulate evidence for a biological basis; (4) institutional reversal occurs — sometimes decades later — repudiating the psychosomatic model and vindicating patient experience. This pattern — the psychosomatic-lag — has played out across ME/CFS (McEvedy 1970 → IOM 2015, 45 years), but also fibromyalgia (~20 years), Gulf War Illness (19 years), multiple sclerosis (>100 years), and Long COVID (~18 months). The compression of the lag over historical time suggests that the pattern is not immutable but reflects remediable failures in medical epistemology: privileging positive laboratory findings over clinical phenomenology, interpreting female predominance as psychogenic rather than immunological, and mistaking absence of evidence for a known pathogen as evidence of absence of disease. The PACE trial controversy demonstrated that this lag is not merely a delay in recognition — it is a period in which psychosomatic treatment models cause active harm. The nomenclature problem (the 1988 CDC decision to name the disorder “chronic fatigue syndrome”) is best understood as an epiphenomenon of the psychosomatic-lag mechanism: once an illness is framed psychosomatically, its name is semantically demoted to reflect a generic symptom rather than a specific disease. The practical implication is clear: medical education should teach the psychosomatic-lag pattern explicitly — “normal labs plus unexplained symptoms does not equal psychiatric disorder” — rather than requiring each disease to fight its own war for recognition.